biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Crisis in biotech - Biodexa addresses needs of the time

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Dec 23, 2022 7:13am

90 Views

Post# 35188952

RE:Crisis in biotech - Biodexa addresses needs of the time

25% of biotech below cash in recent months.

May 2022 there were 240 biotech firms with <1.5 years cash.
December 22 there were 320 biotech firms with <1.5 years cash.

THAT'S A WHOPPING 33% INCREASE IN ABOUT 1/2 YEAR.

WAKE UP PEOPLE!